Haisco Pharmaceutical Group Co., Ltd. (SHE:002653)
54.00
-1.56 (-2.81%)
Nov 17, 2026, 3:04 PM CST
SHE:002653 Revenue
Haisco Pharmaceutical Group had revenue of 1.87B CNY in the quarter ending September 30, 2026, with 44.30% growth. This brings the company's total for the last twelve months to 6.06B, up 41.87% year-over-year. In the year 2025, Haisco Pharmaceutical Group had annual revenue of 4.39B with 17.91% growth. That makes Haisco Pharmaceutical Group the 8,062nd largest company in the world by revenue and 1,220th in China.
Revenue (ttm)
6.06B
Revenue Growth
+41.87%
P/S Ratio
9.97
Revenue / Employee
1.08M
Employees
5,597
Market Cap
59.90B
Revenue by Segment
- Parent Company 4.40B 49.7%
- Tibet Pharmaceuticals Merger 2.55B 28.8%
- Liaoning Hisun 548.14M 6.2%
- Tibet Haize 534.79M 6.0%
- Sichuan Hisun Corporation Merger 530.58M 6.0%
- Shenyang Hisun 287.23M 3.2%
Fiscal year ended Dec 31, 2025 See the full SHE:002653 breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.39B | 666.44M | 17.91% |
| Dec 31, 2024 | 3.72B | 366.28M | 10.92% |
| Dec 31, 2023 | 3.36B | 339.78M | 11.27% |
| Jan 1, 2023 | 3.02B | 241.98M | 8.73% |
| Jan 1, 2022 | 2.77B | -556.28M | -16.71% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
Revenue RankingsHaisco Pharmaceutical Group News
- 20 days ago - Haisco Pharmaceutical Group Quarterly report: Q3 2026 - Filings
- 2 months ago - Haisco Pharmaceutical Group Quarterly report: Q2 2026 - Filings
- 2 months ago - Haisco Enters $1.5 Billion Exclusive License Agreement With Sentivera - Nasdaq
- 4 months ago - Nuvectis gains two experimental drugs in licensing deal with China's Haisco - Reuters
- 5 months ago - Haisco Announces Licensing And Research Collaboration With Lilly - Nasdaq
- 6 months ago - Haisco Pharmaceutical Group Quarterly report: Q1 2026 - Filings
- 6 months ago - Haisco Pharmaceutical Group Annual report: Q4 2025 - Filings
- 7 months ago - As China’s biotech firms shift gears, can AI floor the accelerator? - South China Morning Post